The targeted cancer pill – Gleevec – has been approved for the treatment of gastrointestinal stromal tumors, pediatric CML, as well as five additional rare cancers.
While it has been reported to have saved more than 100,000 lives, Gleevec is now saving more children with a dire leukemia (Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) ), as well as preventing disease progression with long term use in adults with chronic myeloid leukemia (CML).
Such were the data reported by Oregon Health & Science University (OSHU) at the recent annual meeting of the American Society of Hematology:
“Data at this weekend’s meeting continues to …read more